Description

The May 2026 Lancet Diabetes & Endocrinology review by Savas et al. synthesises evidence that obesity medications—particularly GLP‑1 receptor agonists and novel multiagonists—provide broad, clinically meaningful benefits beyond weight loss. Drawing on randomised trials and meta-analyses, the review examines effects across ten organ systems including type 2 diabetes, MASLD, chronic kidney disease, heart failure, cardiovascular disease, obstructive sleep apnoea, PCOS, osteoarthritis, muscle mass, depression, and neurodegeneration. Complementary pooled analyses show GLP‑1 RAs reduce composite kidney outcomes (HR 0.82), major adverse cardiovascular events (HR 0.87), and all‑cause mortality (HR 0.88). Crucially, the authors emphasise accumulating evidence for weight‑loss‑independent mechanisms—direct anti‑inflammatory, renal, and myocardial actions—that explain benefits observed even in non‑diabetic populations (eg, SELECT). The review provides mechanistic and trial-based support for reframing GLP‑1 and multiagonist therapies as systemic disease‑modifying agents, aligning with recent CKM guideline endorsements that integrate metabolic, cardiac, and renal care.